Arteris spent its first post-IPO seasons selling system-level intellectual property - the Network-on-Chip (NoC) interconnect blocks that route data inside the sprawling designs of the AI era - into a market that has now made that business one of the year's most crowded trades. The company's fiscal second quarter arrived as the shares were giving back a five-fold run: after touching a 52-week high near $50 in late June, the stock had fallen to just above $27 by the time this report's numbers were current, a pullback of roughly 45%. The quarter underneath that motion tells a cleaner story than the tape. Revenue rose 46% year over year to $24.1 million, the fastest growth of the recent run, and every forward indicator pointed the same way: Annual Contract Value climbed to $90.9 million from $63.9 million a year earlier, and remaining performance obligations - the contracted revenue still to be recognized - reached $134.9 million, up roughly a third.
The tension is what the income statement does with that growth. GAAP net loss widened to $14.1 million from $9.1 million a year earlier, and the accumulated deficit stands at $193.7 million. Arteris is reinvesting nearly every incremental dollar of license revenue into more engineering headcount and go-to-market spend, and the second quarter added a full period of the January Cycuity acquisition - which brought both its own revenue and a $2.1 million swing in the fair value of that deal's earn-out, booked as acquisition-related cost. At $27 the market is paying roughly 16 times trailing revenue for this - a premium to the profitable EDA and IP names it competes with, justified only if the compounding backlog converts into something closer to break-even. That conversion is the whole question of the next few quarters.